

CME SYMPOSIUM

NSCLC and Emerging Biomarkers: Predictive Role in Personalized Medicine

22nd May 2026

time: 18:45 – 19:45



Event Venue

HABITA79 MGallery Pompei
10 Via Roma, 80045
Pompei (NA), Italy

Steering committee

Umberto Malapelle,
Christian Rolfo

RATIONALE

The characterization of HER2 mutations in patients with non-small cell lung cancer is emerging as a predictive biomarker of response to next-generation targeted therapies. Given the simultaneous assessment of this marker alongside all other essential biomarkers for patients with NSCLC (EGFR, KRAS, BRAF, ALK, ROS1, RET, MET, NTRK and PD-L1), a multidisciplinary discussion is warranted to further explore optimal diagnostic strategies and how to integrate different biological matrices (tissue and liquid biopsy), ensuring that all patients receive appropriate testing.

PROGRAM

18.45 – 19.05	The Evolution of Predictive Biomarkers in Patients with Non-Small Cell Lung Cancer	Christian Rolfo
19.05 – 19.25	The Role of Liquid Biopsy	Umberto Malapelle
19.25 – 19.35	Guided Discussion	Nicola Fusco, Marcello Tiseo
19.35 – 19.45	Conclusions	Umberto Malapelle

STEERING COMMITTEE

Umberto Malapelle,

Associate Professor, Department of Public Health,
University Federico II of Naples

Christian Rolfo,

Director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute


FACULTY

Nicola Fusco,

Director of the Division of Pathology, European Institute of Oncology IRCCS, Associate Professor of Pathology, Department of Oncology and Hemato-Oncology, University of Milan

Marcello Tiseo,

Department of Medicine and Surgery,
University of Parma and Medical Oncology Unit,
University Hospital of Parma, Parma, Italy



NSCLC and Emerging Biomarkers: Predictive Role in Personalized Medicine

CME SYMPOSIUM 2157 – 482253

The project has been awarded **1 educational credit** for the following professional disciplines: **Medical Doctor (specialties: Oncology, Pathology)**.

The training course is accredited for a maximum of **100 participants**.

Credits will be awarded upon documented attendance of at least 90% of the total duration of the program and successful completion of the assessment with at least 75% correct answers. No exceptions will be made to these requirements.

The ECM questionnaire and the perceived quality questionnaire, both mandatory for the assignment of ECM credits, will be available for completion on the platform www.medicaecm.it, no later than 3 days after the end of the event (by May 25, 2026).

REGISTRATION PROCEDURE

Registration is free of charge and entitles participants to attend the congress sessions and receive a certificate of attendance.

Please visit www.medicaecm.it:

- If this is your first access, click on **“Register”** at the top or bottom of the homepage and complete the registration form with your personal details.
- You will receive an automatic confirmation email at the address provided. Then log in to the platform using your credentials and register for the course **“NSCLC and Emerging Biomarkers: Predictive Role in Personalized Medicine”**, available in the list on the homepage.
- To complete the registration, click **“Enter”**.
- For technical assistance or to report any dietary requirements, click on the **“Assistance”** box on the homepage and complete the form.

The training module of this course consists of a residential event that will take place on May 22, 2026, from 6:45 PM to 7:45 PM.

Venue: HABITA79 MGallery Pompeii, Via Roma 10, 80045 Pompei (NA), Italy

With the unconditional support of:



Provider ECM ID 2157
REGOLAMENTO ECN PER LA CREDITAZIONE
Medica - Editoria e Diffusione Scientifica Srl Con Unico Socio
Cassa di Risparmio di Napoli
Piazza S. Bartolomeo 10
I-80132 NAPOLI
F. +39 02 76263377
P. +39 02 50953500
M. info@medicaecm.it
W. www.medicaecm.it